Target General Infomation
Target ID
T59328 (Former ID: TTDS00355)
Target Name
Epidermal growth factor receptor (EGFR)
Synonyms
Receptor tyrosine-protein kinase erbB-1; Proto-oncogene c-ErbB-1; HER1; ERBB1; ERBB
Gene Name
EGFR
Target Type
Successful target
[1]
Disease [+] 9 Target-related Diseases +
1 Angina pectoris [ICD-11: BA40]
2 Breast cancer [ICD-11: 2C60-2C6Y]
3 Colorectal cancer [ICD-11: 2B91]
4 Diabetic foot ulcer [ICD-11: BD54]
5 Ischemia [ICD-11: 8B10-8B11]
6 Lung cancer [ICD-11: 2C25]
7 Renal cell carcinoma [ICD-11: 2C90]
8 Solid tumour/cancer [ICD-11: 2A00-2F9Z]
9 Unspecific body region injury [ICD-11: ND56]
Function
Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin. Plays a role in enhancing learning and memory performance (By similarity).
BioChemical Class
Kinase
UniProt ID
EGFR_HUMAN
EC Number
EC 2.7.10.1
Sequence
MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEV
VLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALA
VLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDF
QNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGC
TGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYV
VTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFK
NCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAF
ENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKL
FGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCN
LLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVM
GENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVV
ALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGS
GAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGI
CLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAA
RNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSY
GVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPK
FRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQ
QGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTED
SIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLN
TVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRV
APQSSEFIGA
Drugs and Modes of Action
Approved Drug(s) [+] 16 Approved Drugs +
1 BIBW 2992 Drug Info Approved Non-small-cell lung cancer [2], [3]
2 Cetuximab Drug Info Approved Colorectal cancer [4], [5]
3 Dacomitinib Drug Info Approved Non-small-cell lung cancer [6]
4 Epidermal growth factor Drug Info Approved Vulnerary [7]
5 Erlotinib Drug Info Approved Non-small-cell lung cancer [5], [8]
6 Gefitinib Drug Info Approved Solid tumour/cancer [9], [10]
7 HEGF Drug Info Approved Diabetic foot ulcer [11]
8 Lapatinib Drug Info Approved Breast cancer [12], [13]
9 Necitumumab Drug Info Approved Colorectal cancer [15], [16]
10 NERATINIB MALEATE Drug Info Approved HER2/NEU overexpressing breast cancer [17]
11 Nitroglycerin Drug Info Approved Diabetic foot ulcer [11]
12 Panitumumab Drug Info Approved Colorectal cancer [18], [19]
13 SKI-758 Drug Info Approved Ischemia [7], [20]
14 Sorafenib Drug Info Approved Renal cell carcinoma [21], [22]
15 Vandetanib Drug Info Approved Solid tumour/cancer [23], [24]
16 Icotinib hydrochloride Drug Info Registered Non-small-cell lung cancer [25], [26], [27]
Clinical Trial Drug(s) [+] 53 Clinical Trial Drugs +
1 Merimepodib Drug Info Approved Breast cancer [14]
2 AZD9291 Drug Info Phase 3 Melanoma [28], [29]
3 Bevacizumab + Erlotinib Drug Info Phase 3 Metastatic colorectal cancer [30], [31]
4 CO-1686 Drug Info Phase 3 Non-small-cell lung cancer [32], [33], [34]
5 DE-766 Drug Info Phase 3 Non-small-cell lung cancer [35], [36]
6 EGF816 Drug Info Phase 3 Non-small-cell lung cancer [37]
7 HKI-272 Drug Info Phase 3 Breast cancer [38], [37]
8 Rindopepimut Drug Info Phase 3 Glioblastoma multiforme [39]
9 SYM-004 Drug Info Phase 3 Metastatic colorectal cancer [37]
10 Zalutumumab Drug Info Phase 3 Head and neck cancer [40]
11 Indium-111 Drug Info Phase 2/3 Solid tumour/cancer [41]
12 Varlitinib Drug Info Phase 2/3 Metastatic biliary tract neoplasms [37]
13 ABT-414 Drug Info Phase 2 Glioblastoma multiforme [42], [43]
14 ASP8273 Drug Info Phase 2 Non-small-cell lung cancer [44]
15 BMS-599626 Drug Info Phase 2 Solid tumour/cancer [45], [46]
16 BMS-690514 Drug Info Phase 2 Chronic pain [47]
17 CetuGEX Drug Info Phase 2 Solid tumour/cancer [48]
18 CI-1033 Drug Info Phase 2 Lymphoma [49], [50]
19 HER1-VSSP vaccine Drug Info Phase 2 Solid tumour/cancer [51], [52]
20 HM-78136B Drug Info Phase 2 Solid tumour/cancer [53], [54]
21 Matuzumab Drug Info Phase 2 Gastric adenocarcinoma [55]
22 MEHD-7945A Drug Info Phase 2 Colorectal cancer [56], [57]
23 Pazopanib + Tyverb/Tykerb Drug Info Phase 2 Inflammatory breast cancer [58]
24 Pelitinib Drug Info Phase 2 Lymphoma [59], [60]
25 RM-1929 Drug Info Phase 2 Head and neck cancer [37], [61]
26 TT-100 Drug Info Phase 2 Non-small-cell lung cancer [62]
27 VATALANIB Drug Info Phase 2 Solid tumour/cancer [63], [64]
28 CART-EGFR Drug Info Phase 1/2 Solid tumour/cancer [65]
29 EGFR CART Drug Info Phase 1/2 Colorectal cancer [66]
30 EMD 55900 Drug Info Phase 1/2 Glioma [67]
31 SN-32793 Drug Info Phase 1/2 Non-small-cell lung cancer [68]
32 Sym013 Drug Info Phase 1/2 Epithelial ovarian cancer [37]
33 Sym015 Drug Info Phase 1/2 Solid tumour/cancer [61], [37]
34 S-222611 Drug Info Phase 1b Malignant solid tumour [69]
35 AMG 595 Drug Info Phase 1 Glioblastoma multiforme [70]
36 Anti-EGFR CAR T Drug Info Phase 1 Glioma [71]
37 Anti-HER3/EGFR DAF Drug Info Phase 1 Metastatic epithelial tumour [72]
38 AP32788 Drug Info Phase 1 Non-small-cell lung cancer [37]
39 AST-1306 Drug Info Phase 1 Solid tumour/cancer [73]
40 BIBX-1382 Drug Info Phase 1 Chronic lymphocytic leukaemia [74], [75]
41 Cipatinib Drug Info Phase 1 Solid tumour/cancer [76]
42 CUDC-101 Drug Info Phase 1 Solid tumour/cancer [77]
43 Depatuxizumab Drug Info Phase 1 Solid tumour/cancer [61]
44 EGFR806-specific CAR T cell Drug Info Phase 1 Atypical teratoid/rhabdoid tumour [78]
45 HER-2/HER-1 vaccine Drug Info Phase 1 Solid tumour/cancer [79]
46 IMGN289 Drug Info Phase 1 Solid tumour/cancer [80]
47 JNJ-26483327 Drug Info Phase 1 Solid tumour/cancer [81]
48 LY3164530 Drug Info Phase 1 Advanced cancer [82]
49 MM-151 Drug Info Phase 1 Solid tumour/cancer [83]
50 MR1-1 Drug Info Phase 1 Brain cancer [84]
51 PF-05230907 Drug Info Phase 1 Nontraumatic intracerebral hemorrhage [85]
52 Rogaratinib Drug Info Phase 1 Solid tumour/cancer [37]
53 SYN004 Drug Info Phase 1 Solid tumour/cancer [61], [37]
Discontinued Drug(s) [+] 8 Discontinued Drugs +
1 PKI166 Drug Info Discontinued in Phase 2 Esophageal cancer [86], [87]
2 RG7160 Drug Info Discontinued in Phase 2 Metastatic colorectal cancer [88]
3 AZD4769 Drug Info Discontinued in Phase 1 Solid tumour/cancer [89]
4 PD-153035 Drug Info Discontinued in Phase 1 Psoriasis vulgaris [90]
5 TAK165 Drug Info Discontinued in Phase 1 Solid tumour/cancer [91], [92]
6 AZD-9935 Drug Info Terminated Solid tumour/cancer [96]
7 CGP-52411 Drug Info Terminated Solid tumour/cancer [97]
8 Heparin-EGF-like factor Drug Info Terminated Gastrointestinal disease [98], [99]
Preclinical Drug(s) [+] 2 Preclinical Drugs +
1 111In-hEGF Drug Info Preclinical Breast cancer [93], [94]
2 EGFR/IGFR tandem adnectin Drug Info Preclinical Solid tumour/cancer [95]
Mode of Action [+] 6 Modes of Action +
Inhibitor [+] 118 Inhibitor drugs +
1 BIBW 2992 Drug Info [100]
2 Erlotinib Drug Info [104]
3 Gefitinib Drug Info [105], [106]
4 Lapatinib Drug Info [107], [108]
5 SKI-758 Drug Info [111]
6 Sorafenib Drug Info [112]
7 Vandetanib Drug Info [113], [114]
8 AZD9291 Drug Info [116]
9 Bevacizumab + Erlotinib Drug Info [117]
10 EGF816 Drug Info [119]
11 HKI-272 Drug Info [120]
12 Merimepodib Drug Info [123]
13 ASP8273 Drug Info [126]
14 BMS-599626 Drug Info [127], [113]
15 BMS-690514 Drug Info [128]
16 CI-1033 Drug Info [113]
17 HM-78136B Drug Info [37], [129]
18 Pazopanib + Tyverb/Tykerb Drug Info [123]
19 TT-100 Drug Info [134]
20 VATALANIB Drug Info [120]
21 SN-32793 Drug Info [103]
22 S-222611 Drug Info [69]
23 AP32788 Drug Info [37]
24 IMGN289 Drug Info [141]
25 JNJ-26483327 Drug Info [142]
26 PF-05230907 Drug Info [34]
27 Rogaratinib Drug Info [37]
28 SYN004 Drug Info [61]
29 Pyrrolo[2,3-d]pyrimidine derivative 24 Drug Info [144]
30 AZD4769 Drug Info [114]
31 TAK165 Drug Info [113]
32 EGFR/IGFR tandem adnectin Drug Info [149]
33 CGP-52411 Drug Info [151]
34 CGP-53353 Drug Info [152]
35 (3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine Drug Info [153]
36 (3-Bromo-phenyl)-quinazolin-4-yl-amine Drug Info [154]
37 (E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin Drug Info [155]
38 (S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate Drug Info [156]
39 10-hydroxy-18-methoxybetaenone Drug Info [157]
40 2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile Drug Info [158]
41 2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile Drug Info [158]
42 2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile Drug Info [156]
43 2-cyano-3-(3,4-dihydroxyphenyl)acrylamide Drug Info [156]
44 2-methoxy-4-(2-nitrovinyl)phenol Drug Info [156]
45 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione Drug Info [159]
46 3,4-diphenyl-1H-pyrrole-2,5-dione Drug Info [159]
47 3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one Drug Info [160]
48 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione Drug Info [159]
49 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione Drug Info [159]
50 3-Pyridin-4-yl-quinoline-6,7-diol Drug Info [161]
51 4-(2-nitroprop-1-enyl)benzene-1,2-diol Drug Info [156]
52 4-(2-nitrovinyl)benzene-1,2-diol Drug Info [156]
53 4-(2-nitrovinyl)phenol Drug Info [156]
54 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline Drug Info [162]
55 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline Drug Info [162]
56 4-(3-Bromo-phenylamino)-quinazoline-6,7-diol Drug Info [154]
57 4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid Drug Info [156]
58 4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline Drug Info [163]
59 4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide Drug Info [164]
60 4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline Drug Info [165]
61 4557W Drug Info [166]
62 5,6-Bis-p-tolylamino-isoindole-1,3-dione Drug Info [152]
63 5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide Drug Info [164]
64 6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline Drug Info [165]
65 6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline Drug Info [165]
66 6,7-diethoxy-4-styrylquinazoline Drug Info [165]
67 6,7-dimethoxy-4-(2-phenylethynyl)quinazoline Drug Info [165]
68 6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline Drug Info [165]
69 6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline Drug Info [165]
70 6,7-dimethoxy-N-m-tolylquinazolin-4-amine Drug Info [167]
71 6-chloro-N-(3-chlorophenyl)quinazolin-4-amine Drug Info [168]
72 AG 112 Drug Info [169]
73 AG 9 Drug Info [169]
74 AG-213 Drug Info [163]
75 AG-538 Drug Info [156]
76 Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine Drug Info [154]
77 Benzyl-quinazolin-4-yl-amine Drug Info [153]
78 BPIQ-I Drug Info [154]
79 CL-387785 Drug Info [167]
80 Cochliobolic acid Drug Info [170]
81 EGFR inhibitor Drug Info [171]
82 Epitinib Drug Info [103]
83 HDS-029 Drug Info [172]
84 HKI-9924129 Drug Info [173]
85 HM-61713B Drug Info [103]
86 HTS-00213 Drug Info [167]
87 HTS-02876 Drug Info [167]
88 HTS-05058 Drug Info [171]
89 LAVENDUSTIN A Drug Info [174]
90 MDP-01 Drug Info [103]
91 MT-062 Drug Info [103]
92 N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine Drug Info [154]
93 N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine Drug Info [176]
94 N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine Drug Info [153]
95 N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine Drug Info [177]
96 N-(4-(phenylamino)quinazolin-6-yl)acrylamide Drug Info [178]
97 N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide Drug Info [179]
98 N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide Drug Info [179]
99 N4-(3-chlorophenyl)quinazoline-4,6-diamine Drug Info [180]
100 N4-(3-methylphenyl)-4,6-quinazolinediamine Drug Info [181]
101 NRC-2694 Drug Info [103]
102 ON-128 Drug Info [103]
103 OSI-75 Drug Info [182]
104 PD-0166326 Drug Info [173]
105 PD-0173956 Drug Info [173]
106 PD-158780 Drug Info [177]
107 PD-168393 Drug Info [178]
108 PD182905 Drug Info [183]
109 PMID24915291C38 Drug Info [185]
110 PMID8568816C56 Drug Info [186]
111 PP121 Drug Info [187]
112 RG-50810 Drug Info [156]
113 RM-6427 Drug Info [103]
114 Ro-4396686 Drug Info [188]
115 Theliatinib Drug Info [103]
116 TYRPHOSTIN AG-1478 Drug Info [160]
117 WHI-P154 Drug Info [189]
118 WZ-3146 Drug Info [103]
Antagonist [+] 13 Antagonist drugs +
1 Dacomitinib Drug Info [103]
2 NERATINIB MALEATE Drug Info [17]
3 Icotinib hydrochloride Drug Info [115]
4 Sym013 Drug Info [61], [37]
5 Sym015 Drug Info [61]
6 BIBX-1382 Drug Info [140]
7 Depatuxizumab Drug Info [61]
8 MM-151 Drug Info [61]
9 RM-1929 Drug Info [37]
10 AZD-9935 Drug Info [150]
11 EDP-13 Drug Info [103]
12 IPS-01003 Drug Info [103]
13 RX-1792 Drug Info [103]
Modulator [+] 29 Modulator drugs +
1 Epidermal growth factor Drug Info [103]
2 Necitumumab Drug Info [109]
3 CO-1686 Drug Info [118]
4 DE-766 Drug Info [103]
5 Rindopepimut Drug Info [109]
6 Varlitinib Drug Info [122]
7 MEHD-7945A Drug Info [122], [131]
8 Pelitinib Drug Info [132]
9 AMG 595 Drug Info [135]
10 Anti-HER3/EGFR DAF Drug Info [136]
11 AST-1306 Drug Info [137], [138], [139]
12 Cipatinib Drug Info [122]
13 CUDC-101 Drug Info [77]
14 LY3164530 Drug Info [131]
15 MR1-1 Drug Info [143]
16 PKI166 Drug Info [145]
17 RG7160 Drug Info [146]
18 PD-153035 Drug Info [147]
19 111In-hEGF Drug Info [148]
20 Heparin-EGF-like factor Drug Info [98], [99]
21 AGT-2000 Drug Info [103]
22 AL-6802 Drug Info [103]
23 Imaging-theranostic nanoemulsion agents Drug Info [103]
24 LA22-radioimmunoconjugates Drug Info [103]
25 MG-111 Drug Info [175]
26 PF 5208766 Drug Info [184]
27 Small-molecule cetuximab binding mimics Drug Info [103]
28 SYM-011 Drug Info [103]
29 TGF alpha Drug Info [103]
Activator [+] 2 Activator drugs +
1 HEGF Drug Info [11]
2 Nitroglycerin Drug Info [11]
Suppressor [+] 1 Suppressor drugs +
1 Panitumumab Drug Info [110]
CAR-T-Cell-Therapy [+] 4 CAR-T-Cell-Therapy drugs +
1 CART-EGFR Drug Info [65]
2 EGFR CART Drug Info [66]
3 Anti-EGFR CAR T Drug Info [71]
4 EGFR806-specific CAR T cell Drug Info [78]
Target Regulators
Target-regulating microRNAs
Target-regulating Transcription Factors
Target-interacting Proteins
Target Profiles in Patients
Target Expression
 Profile (TEP)
Drug Resistance
 Mutation (DRM)
Target Affiliated Biological Pathways
KEGG Pathway [+] 32 KEGG Pathways +
1 MAPK signaling pathway
2 ErbB signaling pathway
3 Ras signaling pathway
4 Rap1 signaling pathway
5 Calcium signaling pathway
6 Cytokine-cytokine receptor interaction
7 HIF-1 signaling pathway
8 FoxO signaling pathway
9 Endocytosis
10 PI3K-Akt signaling pathway
11 Dorso-ventral axis formation
12 Focal adhesion
13 Adherens junction
14 Gap junction
15 Regulation of actin cytoskeleton
16 GnRH signaling pathway
17 Estrogen signaling pathway
18 Oxytocin signaling pathway
19 Epithelial cell signaling in Helicobacter pylori infection
20 Hepatitis C
21 Pathways in cancer
22 Proteoglycans in cancer
23 MicroRNAs in cancer
24 Pancreatic cancer
25 Endometrial cancer
26 Glioma
27 Prostate cancer
28 Melanoma
29 Bladder cancer
30 Non-small cell lung cancer
31 Central carbon metabolism in cancer
32 Choline metabolism in cancer
NetPath Pathway [+] 2 NetPath Pathways +
1 IL4 Signaling Pathway
2 EGFR1 Signaling Pathway
Panther Pathway [+] 2 Panther Pathways +
1 Cadherin signaling pathway
2 EGF receptor signaling pathway
PID Pathway [+] 19 PID Pathways +
1 LPA receptor mediated events
2 Signaling events mediated by PTP1B
3 Arf6 signaling events
4 Signaling events mediated by TCPTP
5 Thromboxane A2 receptor signaling
6 SHP2 signaling
7 Regulation of Telomerase
8 EGF receptor (ErbB1) signaling pathway
9 EGFR-dependent Endothelin signaling events
10 Posttranslational regulation of adherens junction stability and dissassembly
11 Direct p53 effectors
12 ErbB1 downstream signaling
13 Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
14 E-cadherin signaling in keratinocytes
15 ErbB receptor signaling network
16 Internalization of ErbB1
17 Stabilization and expansion of the E-cadherin adherens junction
18 a6b1 and a6b4 Integrin signaling
19 Syndecan-3-mediated signaling events
Reactome [+] 14 Reactome Pathways +
1 Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
2 SHC1 events in ERBB2 signaling
3 PLCG1 events in ERBB2 signaling
4 PIP3 activates AKT signaling
5 GRB2 events in EGFR signaling
6 GAB1 signalosome
7 SHC1 events in EGFR signaling
8 EGFR downregulation
9 GRB2 events in ERBB2 signaling
10 PI3K events in ERBB2 signaling
11 EGFR Transactivation by Gastrin
12 Constitutive Signaling by Aberrant PI3K in Cancer
13 Constitutive Signaling by EGFRvIII
14 RAF/MAP kinase cascade
WikiPathways [+] 29 WikiPathways +
1 ErbB Signaling Pathway
2 Regulation of Actin Cytoskeleton
3 EGF/EGFR Signaling Pathway
4 MAPK Signaling Pathway
5 Focal Adhesion
6 Aryl Hydrocarbon Receptor Pathway
7 Extracellular vesicle-mediated signaling in recipient cells
8 TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer
9 Hair Follicle Development: Cytodifferentiation (Part 3 of 3)
10 Bladder Cancer
11 Hair Follicle Development: Induction (Part 1 of 3)
12 Signaling by ERBB4
13 Signaling by ERBB2
14 Gastrin-CREB signalling pathway via PKC and MAPK
15 PIP3 activates AKT signaling
16 Nanoparticle-mediated activation of receptor signaling
17 Aryl Hydrocarbon Receptor
18 Spinal Cord Injury
19 Integrated Pancreatic Cancer Pathway
20 Gastric cancer network 2
21 AGE/RAGE pathway
22 Signaling Pathways in Glioblastoma
23 Arylhydrocarbon receptor (AhR) signaling pathway
24 miR-targeted genes in muscle cell - TarBase
25 miR-targeted genes in lymphocytes - TarBase
26 miR-targeted genes in epithelium - TarBase
27 Integrated Breast Cancer Pathway
28 Signaling by EGFR
29 L1CAM interactions
Target-Related Models and Studies
Target Validation
Target QSAR Model
References
REF 1 Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Mol Cancer Ther. 2002 May;1(7):507-14.
REF 2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5667).
REF 3 BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors. Curr Opin Investig Drugs. 2008 Dec;9(12):1336-46.
REF 4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6882).
REF 5 2004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4.
REF 6 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
REF 7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
REF 8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4920).
REF 9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4941).
REF 10 Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
REF 11 Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
REF 12 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5692).
REF 13 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022059.
REF 14 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022059.
REF 15 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8090).
REF 16 ClinicalTrials.gov (NCT00981058) First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin. U.S. National Institutes of Health.
REF 17 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
REF 18 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6883).
REF 19 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
REF 20 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
REF 21 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5711).
REF 22 Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 2006;407:597-612.
REF 23 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5717).
REF 24 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
REF 25 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7641).
REF 26 Clinical pipeline report, company report or official report of Beta Pharma.
REF 27 ClinicalTrials.gov (NCT02404675) High Dose Icotinib in Advanced Non-small Cell Lung Cancer Patients With EGFR 21 Exon Positive. U.S. National Institutes of Health.
REF 28 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7719).
REF 29 ClinicalTrials.gov (NCT02511106) AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.
REF 30 ClinicalTrials.gov (NCT00130728) A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
REF 31 ClinicalTrials.gov (NCT00598156) Chemotherapy and Avastin Followed by Maintenance Treatment With Avastin +/- Tarceva
REF 32 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7966).
REF 33 ClinicalTrials.gov (NCT02322281) TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy. U.S. National Institutes of Health.
REF 34 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
REF 35 Clinical pipeline report, company report or official report of Daiichi Sankyo.
REF 36 Clinical pipeline report, company report or official report of Daiichi Sankyo.
REF 37 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
REF 38 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021154)
REF 39 ClinicalTrials.gov (NCT01480479) Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma. U.S. National Institutes of Health.
REF 40 ClinicalTrials.gov (NCT00382031) Zalutumumab in Patients With Non-curable Head and Neck Cancer. U.S. National Institutes of Health.
REF 41 ClinicalTrials.gov (NCT00442533) Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors. U.S. National Institutes of Health.
REF 42 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7970).
REF 43 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035129)
REF 44 ClinicalTrials.gov (NCT02500927) A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations.
REF 45 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7647).
REF 46 ClinicalTrials.gov (NCT01614522) A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1and HER-2. U.S. National Institutes of Health.
REF 47 A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. Cancer Res. 2007 Jul 1;67(13):6253-62.
REF 48 Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther. 2011 May 1;11(9):777-92.
REF 49 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5675).
REF 50 Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. J Med Chem. 2000 Apr 6;43(7):1380-97.
REF 51 Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant. Int J Cancer. 2006 Nov 1;119(9):2190-9.
REF 52 HER1-ECD vaccination dispenses with emulsification to elicit HER1-specific anti-proliferative effects. Hum Vaccin. 2009 Mar;5(3):158-65.
REF 53 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7903).
REF 54 ClinicalTrials.gov (NCT02216916) Phase II Trial of HM781-36B in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of or Unfit for Platinum-containing Therapy. U.S. National Institutes of Health.
REF 55 ClinicalTrials.gov (NCT00073541) A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian Cancer. U.S. National Institutes of Health.
REF 56 ClinicalTrials.gov (NCT01577173) A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck
REF 57 ClinicalTrials.gov (NCT01652482) A Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wild-Type Metastatic Colorectal Cancer. U.S. National Institutes of Health.
REF 58 A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer. Breast Cancer Res Treat. 2013 Jan;137(2):471-82.
REF 59 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7644).
REF 60 ClinicalTrials.gov (NCT00067548) Study Evaluating EKB-569 in Advanced Non-Small Cell Lung Cancer. U.S. National Institutes of Health.
REF 61 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
REF 62 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021633)
REF 63 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5705).
REF 64 ClinicalTrials.gov (NCT00348790) Vatalanib in Treating Patients With Recurrent or Progressive Meningioma. U.S. National Institutes of Health.
REF 65 ClinicalTrials.gov (NCT01869166) Treatment of Chemotherapy Refractory EGFR(Epidermal Growth Factor Receptor) Positive Advanced Solid Tumors (CART-EGFR)
REF 66 ClinicalTrials.gov (NCT03152435) EGFR CART Cells for Patients With Metastatic Colorectal Cancer
REF 67 Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55,900) in patients with recurrent malignant gliomas. Eur J Cancer. 1996 Apr;32A(4):636-40.
REF 68 ClinicalTrials.gov (NCT01631279) A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors. U.S. National Institutes of Health.
REF 69 Clinical pipeline report, company report or official report of Shionogi (2011).
REF 70 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020588)
REF 71 ClinicalTrials.gov (NCT02331693) CAR T Cells in Treating Patients With Malignant Gliomas Overexpressing EGFR
REF 72 Clinical pipeline report, company report or official report of Genentech (2011).
REF 73 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032292)
REF 74 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7646).
REF 75 ClinicalTrials.gov (NCT00003980) BIBX 1382 in Treating Patients With Solid Tumors. U.S. National Institutes of Health.
REF 76 ClinicalTrials.gov (NCT01301911) Study of Cipatinib in Patients With HER2 Positive or Uncertain Advanced Breast Cancer. U.S. National Institutes of Health.
REF 77 A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Apr 1;21(7):1566-73.
REF 78 ClinicalTrials.gov (NCT03638167) EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors
REF 79 Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC). Vaccines (Basel). 2015 Jul 6;3(3):519-43.
REF 80 ClinicalTrials.gov (NCT01963715) A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors. U.S. National Institutes of Health.
REF 81 ClinicalTrials.gov (NCT00676299) A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies.. U.S. National Institutes of Health.
REF 82 ClinicalTrials.gov (NCT02221882) A Study of LY3164530 in Participants With Cancer
REF 83 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035447)
REF 84 ClinicalTrials.gov (NCT01009866) Study of Immunotoxin, MR1-1. U.S. National Institutes of Health.
REF 85 ClinicalTrials.gov (NCT02537002) Single Dose Study of PF-05230907 in Healthy Japanese Subjects.
REF 86 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7642).
REF 87 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013689)
REF 88 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029052)
REF 89 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024847)
REF 90 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005268)
REF 91 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6011).
REF 92 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019257)
REF 93 A comparison of non-biologically active truncated EGF (EGFt) and full-length hEGF for delivery of Auger electron-emitting 111In to EGFR-positive br... Nucl Med Biol. 2015 Dec;42(12):931-8.
REF 94 Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer. J Nucl Med. 2006 Jun;47(6):1023-31.
REF 95 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026610)
REF 96 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018392)
REF 97 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004971)
REF 98 The heparin-binding domain of heparin-binding EGF-like growth factor can target Pseudomonas exotoxin to kill cells exclusively through heparan sulfate proteoglycans. J Cell Sci. 1994 Sep;107 ( Pt 9):2599-608.
REF 99 Heparin-binding epidermal growth factor-like growth factor is an autocrine growth factor for human keratinocytes. J Biol Chem. 1994 Aug 5;269(31):20060-6.
REF 100 Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
REF 101 Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin Oncol. 2002 Oct;29(5 Suppl 14):31-7.
REF 102 Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol. 2002 Feb;29(1 Suppl 4):27-36.
REF 103 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
REF 104 Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
REF 105 Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.
REF 106 Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC). Semin Cancer Biol. 2004 Feb;14(1):33-40.
REF 107 Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
REF 108 Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.
REF 109 Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme. Curr Opin Mol Ther. 2010 Dec;12(6):741-54.
REF 110 Integration of panitumumab into the treatment of colorectal cancer. Crit Rev Oncol Hematol. 2010 Apr;74(1):16-26.
REF 111 Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
REF 112 Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
REF 113 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
REF 114 Clinical pipeline report, company report or official report of AstraZeneca (2009).
REF 115 Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Lung Cancer. 2011 Aug;73(2):195-202.
REF 116 AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014 Sep;4(9):1046-61.
REF 117 Clinical pipeline report, company report or official report of Roche (2009).
REF 118 Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015 Apr 30;372(18):1700-9.
REF 119 Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov. 2013 Dec;3(12):1404-15.
REF 120 Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cyst... Bioorg Med Chem. 2007 Jun 1;15(11):3635-48.
REF 121 Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody. Mol Cancer Ther. 2015 May;14(5):1141-51.
REF 122 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
REF 123 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
REF 124 Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development. Mar Drugs. 2014 January; 12(1): 255-278.
REF 125 Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer. 2002 Mar 1;94(5):1593-611.
REF 126 Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation positive NSCLC, Journal of Clinical Oncology, Vol 33, No 15_suppl (May 20 Supplement), 2015: 8083.
REF 127 AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo. Invest New Drugs. 2011 Aug;29(4):554-61.
REF 128 Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci. 2010 Aug;99(8):3579-93.
REF 129 Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models. Int J Cancer. 2012 May 15;130(10):2445-54.
REF 130 Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. Cancer Cell. 2008 Apr;13(4):365-73.
REF 131 Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
REF 132 EGFR tyrosine kinase inhibitor pelitinib regulates radiation-induced p65-dependent telomerase activation in squamous cell carcinoma.Radiat Res.2013 Mar;179(3):304-12.
REF 133 Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab. Neoplasia. 2013 Oct;15(10):1196-206.
REF 134 BiPar Sciences Co-founder Reunites Management Team At TriAct Therapeutics to Advance Clinical Stage Cancer Programs. TriAct Therapeutics. Sept. 10, 2009.
REF 135 AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma. Mol Cancer Ther. 2015 Jul;14(7):1614-24.
REF 136 Company report (Biooncology)
REF 137 AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo. PLoS One. 2011;6(7):e21487.
REF 138 Development and validation of a sensitive LC-MS/MS assay for the simultaneous quantification of allitinib and its two metabolites in human plasma.J Pharm Biomed Anal.2013 Dec;86:49-55.
REF 139 Metabolism and pharmacokinetics of allitinib in cancer patients: the roles of cytochrome P450s and epoxide hydrolase in its biotransformation.Drug Metab Dispos.2014 May;42(5):872-84.
REF 140 Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. Eur J Cancer. 2002 May;38(8):1072-80.
REF 141 World Antibody-Drug Conjugate Summit, October 15-16, 2013, San Francisco, CA. MAbs. 2014 January 1; 6(1): 18-29.
REF 142 National Cancer Institute Drug Dictionary (drug id 596693).
REF 143 A Phase I Study of Immunotoxin, MR1-1. Duke University report.
REF 144 Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318.
REF 145 Epidermal growth factor receptor inhibitor PKI-166 governs cardiovascular protection without beneficial effects on the kidney in hypertensive 5/6 nephrectomized rats.J Pharmacol Exp Ther.2013 Jun;345(3):393-403.
REF 146 GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab. Clin Cancer Res. 2013 Mar 1;19(5):1126-38.
REF 147 EGFR tyrosine kinase inhibitor (PD153035) improves glucose tolerance and insulin action in high-fat diet-fed mice.Diabetes.2009 Dec;58(12):2910-9.
REF 148 A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer. J Nucl Med. 2000 May;41(5):903-11.
REF 149 Clinical pipeline report, company report or official report of Bristol-Myers Squibb.
REF 150 WO patent application no. 2009,0582,67, Benzomorpholine derivatives and methods of use.
REF 151 Retinoic acid-induced RB (retinoblastoma) hypophosphorylation enhanced by CGP 52411 (4,5-dianilinophthalimide), an EGF family tyrosine kinase receptor inhibitor. Eur J Cell Biol. 1996 Apr;69(4):327-34.
REF 152 Dianilinophthalimides: potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase. J Med Chem. 1994 Apr 1;37(7):1015-27.
REF 153 Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as poten... J Med Chem. 1995 Sep 1;38(18):3482-7.
REF 154 Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase acti... J Med Chem. 1996 Feb 16;39(4):918-28.
REF 155 5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line. Eur J Med Chem. 2009 Sep;44(9):3471-9.
REF 156 Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents. J Nat Prod. 1992 Nov;55(11):1529-60.
REF 157 Anthraquinones and betaenone derivatives from the sponge-associated fungus Microsphaeropsis species: novel inhibitors of protein kinases. J Nat Prod. 2000 Jun;63(6):739-45.
REF 158 Tyrphostins. 2. Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine... J Med Chem. 1991 Jun;34(6):1896-907.
REF 159 Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
REF 160 Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: isoflavones and 3-phenyl-4(1H)-quinolones. J Med Chem. 1999 Mar 25;42(6):1018-26.
REF 161 5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9.
REF 162 A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
REF 163 Syntheses of 4-(indole-3-yl)quinazolines: a new class of epidermal growth factor receptor tyrosine kinase inhibitors. Eur J Med Chem. 2008 Jul;43(7):1478-88.
REF 164 Acryloylamino-salicylanilides as EGFR PTK inhibitors. Bioorg Med Chem Lett. 2006 Jan 15;16(2):469-72.
REF 165 Synthesis and inhibitory activity of 4-alkynyl and 4-alkenylquinazolines: identification of new scaffolds for potent EGFR tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5863-7.
REF 166 Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2. Bioorg Med Chem Lett. 2001 Jun 4;11(11):1401-5.
REF 167 Computational studies of epidermal growth factor receptor: docking reliability, three-dimensional quantitative structure-activity relationship anal... J Med Chem. 2009 Feb 26;52(4):964-75.
REF 168 Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6.
REF 169 Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors. J Med Chem. 1989 Oct;32(10):2344-52.
REF 170 Cochliobolic acid, a novel metabolite produced by Cochliobolus lunatus, inhibits binding of TGF-alpha to the EGF receptor in a SPA assay. J Nat Prod. 1997 Jan;60(1):6-8.
REF 171 A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
REF 172 Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB... J Med Chem. 2006 Feb 23;49(4):1475-85.
REF 173 Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
REF 174 Novel antiproliferative agents derived from lavendustin A. J Med Chem. 1994 Nov 25;37(24):4079-84.
REF 175 Effects of hEGF (MG111) on gastric mucosal potential difference in rats. Scand J Gastroenterol Suppl. 1989;162:198-201.
REF 176 Synthesis of a prodrug designed to release multiple inhibitors of the epidermal growth factor receptor tyrosine kinase and an alkylating agent: a n... J Med Chem. 2003 Dec 4;46(25):5546-51.
REF 177 Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinas... J Med Chem. 1996 Apr 26;39(9):1823-35.
REF 178 Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nat Chem Biol. 2007 Apr;3(4):229-38.
REF 179 Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP... J Med Chem. 1999 May 20;42(10):1803-15.
REF 180 Novel nitrogen mustard-armed combi-molecules for the selective targeting of epidermal growth factor receptor overexperessing solid tumors: discover... J Med Chem. 2007 May 31;50(11):2605-8.
REF 181 The combi-targeting concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR). J Med Chem. 2006 Jun 15;49(12):3544-52.
REF 182 Selected novel anticancer treatments targeting cell signaling proteins. Oncologist. 2001;6(6):517-37.
REF 183 Growth factors and their receptors: new targets for prostate cancer therapy. Urology. 2001 Aug;58(2 Suppl 1):114-22.
REF 184 Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor... J Med Chem. 2005 Feb 24;48(4):1107-31.
REF 185 Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28.
REF 186 Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J Med Chem. 1996 Jan 5;39(1):267-76.
REF 187 Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9.
REF 188 Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.
REF 189 The specificity of JAK3 kinase inhibitors. Blood. 2008 Feb 15;111(4):2155-7.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Wang and Dr. Li.